Skip to content

Study · Animal study (in vivo) · rat · 1986

1 result

Vasopressin and oxytocin reduce plasma prolactin levels of conscious rats in basal and stress conditions. Study of the characteristics of the receptor involved.

Mormede P, Vincent JD, Kerdelhue B

Life sciences1 Nov 1986Cited by 16 (Europe PMC)

PMID3022094 (opens in a new tab)DOI10.1016/0024-3205(86)90092-5 (opens in a new tab)PepBankPUB-03022094
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, oxytocin also lowered plasma prolactin, but it was 5-fold less potent than arginine vasopressin.

    In plain wordsIn rats, oxytocin lowered blood prolactin, but it was 5-fold weaker than vasopressin.

    Peptide
    Oxytocin
    Outcome
    DecreasePlasma prolactin level
    Study

    ratn: not reported in source

    conscious rats
    Comparator
    Arginine vasopressin
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Oxytocin (OT) was also active but 5-fold less potent than AVP.
    2 context sentences
    Title · context
    Vasopressin and oxytocin reduce plasma prolactin levels of conscious rats in basal and stress conditions. Study of the characteristics of the receptor involved.
    Summary · context
    Subcutaneous administration of arginine vasopressin (AVP) to conscious rats induced a dose-dependent increase of plasma ACTH and beta-endorphin levels and decrease of plasma prolactin (PRL) levels 30 min later.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:53 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.